Skip to main content

Advertisement

SpringerLink
Log in

Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer’s disease

  • Alzheimer’s Therapeutics: Neuroprotection
  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Apolipoprotein E (apoE) remains the most important genetic risk factor for the development of Alzheimer’s disease (AD). Still elusive, the role of apoE is under intense investigation. We propose that proteolysis of apoE in the brain leads to two major fragments, N- and C-terminal apoE, each of which would drive a different neuropathological pathway. N-terminal fragments of apoE are implicated in neurotoxicity, and C-terminal fragments might play a role in amyloid deposition and plaque formation. The greater risk of AD associated with the E4 isoform might relate to its greater neurotoxicity. Drugs that either directly inhibit the toxic effects of apoE or prevent the production of apoE fragments may provide novel therapeutic approaches to the treatment of AD and other disorders in which apoE is implicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aizawa Y., Fukatsu R., Takamaru Y., Tsuzuki K., Chiba H., Kobayashi K., Fujii N., and Takahata N. (1997) Aminoterminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer’s disease-affected brains: a possible role for apolipoprotein E in Alzheimer’s disease. Brain Res. 768, 208–214.

    Article  PubMed  CAS  Google Scholar 

  • Amaratunga A., Abraham C. R., Edwards R. B., Sandell J. H., Schreiber B. M., and Fine R. E. (1996) Apolipoprotein E is synthesized in the retina by Muller glial cells, secreted into the vitreous, and rapidly transported into the optic nerve by retinal ganglion cells. J. Biol. Chem. 271, 5628–5632.

    Google Scholar 

  • Bales K. R., Verina T., Cummins D. J., Du Y., Dodel R. C., Saura J., et al. (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 96, 15,233–15,238.

    Article  CAS  Google Scholar 

  • Bazin H. G., Marques M. A., Owens A. P. III, Linhardt R. J., and Crutcher K. A. (2002) Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides. Biochemistry 41, 8203–8211.

    Article  PubMed  CAS  Google Scholar 

  • Bellosta S., Nathan B. P., Orth M., Dong L. M., Mahley R. W., and Pitas R. E. (1995) Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem. 270, 27,063–27,071.

    CAS  Google Scholar 

  • Bennett C., Crawford F., Osborne A., Diaz P., Hoyne J., Lopez R., et al. (1995) Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer’s Disease but is not causative. Am. J. Med. Genet. 60, 1–6.

    Article  PubMed  CAS  Google Scholar 

  • Boyles J. K., Pitas R. E., Wilson E., Mahley R. W., and Taylor J. M. (1985) Apolipoprotein E associated with astrocytic glia of the central nervous system and with non-myelinating glia of the peripheral nervous system. J. Clin. Invest. 76, 1501–1513.

    PubMed  CAS  Google Scholar 

  • Browning P. J., Roberts D. D., Zabrenetzky V., Bryant J., Kaplan M., Washington R. H., et al. (1994) Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi’s sarcoma-like lesions in BALB/c nu/nu mice. J. Exp. Med. 180, 1949–1954.

    Article  PubMed  CAS  Google Scholar 

  • Buttini M., Akeefe H., Lin C., Mahley R. W., Pitas R. E., Wyss-Coray T., and Mucke L. (2000) Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 97, 207–210.

    Article  PubMed  CAS  Google Scholar 

  • Cambon K., Davies H. A., and Stewart M. G. (2000) Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human apolipoprotein E4 transgenic mice. Neuroscience 97, 685–692.

    Article  PubMed  CAS  Google Scholar 

  • Cedazo-Minguez A., Huttinger M., and Cowburn R. F. (2001) Beta-VLDL protects against A beta(1–42) and apoE toxicity in human SH-SY5Y neuroblastoma cells. Neuroreport 12, 201–206.

    Article  PubMed  CAS  Google Scholar 

  • Cho H. S., Hyman B. T., Greenberg S. M., and Rebeck G. W. (2001) Quantification of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation. J. Neuropath. Exp. Neurol. 60, 342–349.

    PubMed  CAS  Google Scholar 

  • Citron M. (2000) Secretases as targets for the treatment of Alzheimer’s disease. Mol. Med. Today 6, 392–397.

    Article  PubMed  CAS  Google Scholar 

  • Clay M. A., Anantharamaiah G. M., Mistry M. J., Balasubramaniam A., and Harmony J. A. (1995) Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry 34, 11,142–11,151.

    Article  CAS  Google Scholar 

  • Colton C. A., Brown C. M., Cook D., Needham L. K., Xu Q., Czapiga M., et al. (2002) APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol. Aging 23, 777.

    Article  PubMed  CAS  Google Scholar 

  • Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923.

    Article  PubMed  CAS  Google Scholar 

  • Crutcher K. A., Clay M. A., Scott S. A., Tian X., Tolar M., and Harmony J. A. (1994) Neurite degeneration elicited by apolipoprotein E peptides. Exp. Neurol. 130, 120–126.

    Article  PubMed  CAS  Google Scholar 

  • Crutcher K. A., Tolar M., Harmony J. A., and Marques M.A. (1997) Anew hypothesis for the role of apolipoprotein E in Alzheimer’s disease pathology, in Alzheimer’s Disease: Biology, Diagnosis and Therapeutics Iqbal B. W. K., ed.), John Wiley & Sons, Chichester.

    Google Scholar 

  • DeKroon R. M. and Armati P. J. (2001) The endosomal trafficking of apolipoprotein e3 and e4 in cultured human brain neurons and astrocytes. Neurobiol. Dis. 8, 78–89.

    Article  PubMed  CAS  Google Scholar 

  • DeMattos R. B., Thorngate F. E., and Williams D. L. (1999) A test of the cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic. J. Neurosci. 19, 2464–2473.

    PubMed  CAS  Google Scholar 

  • Deng J., Rudick V., and Dory L. (1995) Lysosomal degradation and sorting of apolipoprotein E in macrophages. J. Lipid Res. 36, 2129–2140.

    PubMed  CAS  Google Scholar 

  • Dominguez S. R., Miller-Auer H., Reardon C. A., and Meredith S. C. (1999) Peptide model of a highly conserved, N-terminal domain of apolipoprotein E is able to modulate lipoprotein binding to a member of the class A scavenger receptor family. J. Lipid Res. 40, 753–763.

    PubMed  CAS  Google Scholar 

  • Dyer C. A. and Curtiss L. K. (1988) Apoprotein E-rich high density lipoproteins inhibit ovarian androgen synthesis. J. Biol. Chem. 263, 10,965–10,973.

    CAS  Google Scholar 

  • Egensperger R., Kosel S., von Eitzen U., and Graeber M. B. (1998) Microglial activation in Alzheimer disease: Association with APOE genotype. Brain Pathol. 8, 439–447.

    Article  PubMed  CAS  Google Scholar 

  • Farrer L. A., Cupples L. A., van Duijn C. M., Kurz A., Zimmer R., Muller U., et al. (1995) Apolipoprotein E genotype in patients with Alzheimer’s disease: implications for the risk of dementia among relatives. Ann. Neurol. 38, 797–808.

    Article  PubMed  CAS  Google Scholar 

  • Giulian D. (1987) Ameboid microglia as effectors of inflammation in the central nervous system. J. Neurosci. Res. 18, 155–171.

    Article  PubMed  CAS  Google Scholar 

  • Giulian D. and Vaca K. (1993) Inflammatory glia mediate delayed neuronal damage after ischemia in the central nervous system. Stroke 24, 184–190.

    Google Scholar 

  • Giulian D., Haverkamp L. J., Li J., Karshin W. L., Yu J., Tom D., Li X., and Kirkpatrick J. B. (1995) Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem. Int. 27, 119–137.

    Article  PubMed  CAS  Google Scholar 

  • Gutman C. R., Strittmatter W. J., Weisgraber K. H., and Matthew W. D. (1997) Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor. J. Neurosci. 17, 6114–6121.

    PubMed  CAS  Google Scholar 

  • Han S. H., Einstein G., Weisgraber K. H., Strittmatter W. J., Saunders A. M., Pericak-Vance M., et al. (1994a) Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J. Neuropathol. Exp. Neurol. 53, 535–544.

    PubMed  CAS  Google Scholar 

  • Han S. H., Hulette C., Saunders A. M., Einstein G., Pericak-Vance M., Strittmatter W. J., et al. (1994b) Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer’s disease and in age-matched controls. Exp. Neurol. 128, 13–26.

    Article  PubMed  CAS  Google Scholar 

  • Hardy J. (1995) Apolipoprotein E in the genetics and epidemiology of Alzheimer’s disease. Am. J. Med. Genet. 60, 456–460.

    Article  PubMed  CAS  Google Scholar 

  • Hartman R. E., Wozniak D. F., Nardi A., Olney J. W., Sartorius L., and Holtzman D. M. (2001) Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer’s-like neuropathology. Exp. Neurol. 170, 326–344.

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto Y., Jiang H., Niikura T., Ito Y., Hagiwara A., Umezawa K., et al. (2000) Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases. J. Neurosci. 20, 8401–8409.

    PubMed  CAS  Google Scholar 

  • Ho Y. Y., Al-Haideri M., Mazzone T., Vogel T., Presley J. F., Sturley S. L., and Deckelbaum R. J. (2000) Endogenously expressed apolipoprotein E has different effects on cell lipid metabolism as compared to exogenous apolipoprotein E carried on triglyceride-rich particles. Biochemistry 39, 4746–4754.

    Article  PubMed  CAS  Google Scholar 

  • Holtzman D. M., Bales K. R., Tenkova T., Fagan A. M., Parsadanian M., Sartorius L. J., et al. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 97, 2892–2897.

    Article  PubMed  CAS  Google Scholar 

  • Holtzman D. M., Bales K. R., Wu S., Bhat P., Parsadanian M., Fagan A. M., et al. (1999) Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J. Clin. Invest. 103, R15-R21.

    PubMed  CAS  Google Scholar 

  • Holtzman D. M., Pitas R. E., Kilbridge J., Nathan B., Mahley R. W., Bu G., and Schwartz A. L. (1995) Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl. Acad. Sci. USA 92, 9480–9484.

    Article  PubMed  CAS  Google Scholar 

  • Huang Y., Liu X. Q., and Mahley R. W. (2000) Differential effects of cytosolic apolipoprotein (apo) E3 and apoE4 on neurite outgrowth and the cytoskeleton. Neurobiol. of Aging 21, S216.

    Google Scholar 

  • Huang Y., Liu X. Q., Wyss-Coray T., Brecht W. J., Sanan D. A., and Mahley R. W. (2001) Apolipoprotein E fragments present in Alzheimer’s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. U.S.A. 98, 8838–8843.

    Article  PubMed  CAS  Google Scholar 

  • Ignatius M. J., Gebicke-Harter P. J., Skene J. H., Schilling J. W., Weisgraber K. H., Mahley R. W., and Shooter E. M. (1986) Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. USA 83, 1125–1129.

    Article  PubMed  CAS  Google Scholar 

  • Jordan B. D., Relkin N. R., Ravdin L. D., Jacobs A. R., Bennett A., and Gandy S. (1997) Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 278, 136–140.

    Article  PubMed  CAS  Google Scholar 

  • LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., and Frail D. E. (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269, 23,403–23,406.

    CAS  Google Scholar 

  • LaDu M. J., Pederson T. M., Frail D. E., Reardon C. A., Getz G. S., and Falduto M. T. (1995) Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J. Biol. Chem. 270, 9039–9042.

    Article  PubMed  CAS  Google Scholar 

  • Laffont I., Takahashi M., Shibukawa Y., Honke K., Shuvaev V. V., Siest G., et al. (2002) Apolipoprotein E activates Akt pathway in neuro-2a in an isoform-specific manner. Biochem. Biophys. Res. Commun. 292, 83–87.

    Article  PubMed  CAS  Google Scholar 

  • Lins L., Thomas-Soumarmon A., Pillot T., Vandeker-chkhove J., Rosseneu M., and Brasseur R. (1999) Molecular determinants of the interaction between the C-terminal domain of Alzheimer’s beta-amyloid peptide and apolipoprotein E alpha-helices. J. Neurochem. 73, 758–769.

    Article  PubMed  CAS  Google Scholar 

  • Ma J., Brewer H. B., and Potter H. (1996) Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Neurobiol. Aging 17, 773–780.

    Article  Google Scholar 

  • Mackenzie I. R. and Miller L. A. (1994) Senile plaques in temporal lobe epilepsy. Acta Neuropathol. 87, 504–510.

    PubMed  CAS  Google Scholar 

  • Mahley R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622–630.

    Article  PubMed  CAS  Google Scholar 

  • Mahley R. W. and Ji Z. S. (1999) Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40, 1–16.

    PubMed  CAS  Google Scholar 

  • Majack R. A., Castle C. K., Goodman L. V., Weisgraber K. H., Mahley R. W., Shooter E. M., and Gebicke-Haerter P. J. (1988) Expression of apolipoprotein E by cultured vascular smooth muscle cells is controlled by growth state. J. Cell. Biol. 107, 1207–1213.

    Article  PubMed  CAS  Google Scholar 

  • Marques M. A., Tolar A., and Crutcher K. A. (1997a) Apolipoprotein E exhibits isoform-specific neurotoxicity. Alzheimer’s Res. 3, 1–6.

    CAS  Google Scholar 

  • Marques M. A., Tolar M. and Crutcher K. A. Apolipoprotein E neurotoxicity is attenuated by protease inhibitors, in Society of Neuroscience Meeting, Soc. Neurosci. Abstr., vol. 23, part 1, p. 826, 1997.

    Google Scholar 

  • Marques M. A., Tolar M., Harmony J. A., and Crutcher K. A. (1996) A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport 7, 2529–2532.

    Article  Google Scholar 

  • Martinoli M. G., Trojanowski J. Q., Schmidt M. L., Arnold S. E., Fujiwara T. M., Lee V. M., et al. (1995) Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. Acta Neuropathol. 90, 239–243.

    Article  PubMed  CAS  Google Scholar 

  • Martins R. N., Clarnette R., Fisher C., Broe G. A., Brooks W. S., Montgomery P., and Gandy S. E. (1995) ApoE genotypes in Australia: roles in early and late onset Alzheimer’s disease and Down’s syndrome. Neuroreport 6, 1513–1516.

    PubMed  CAS  Google Scholar 

  • McGeer P. L., Rogers J., and McGeer E. G. (1994) Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis. Assoc. Disord. 8, 149–158.

    Article  PubMed  CAS  Google Scholar 

  • Michikawa M. and Yanagisawa K. (1998) Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. J. Neurosci. Res. 54, 58–67.

    Article  PubMed  CAS  Google Scholar 

  • Miyata M. and Smith J. D. (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14, 55–61.

    Article  Google Scholar 

  • Nadig P., Fine R., and McKee A. Relative invulnerability of apoE knockout mouse hippo- campal neurons to amyloid beta toxicity, in Society of Neurosciences Meeting, Soc. Neurosci. Abstr., Society for Neuroscience, Washington, DC, vol. 22, part 3, p. 1696, 1996.

  • Naidu A., Catalano R., Bales K., Wu S., Paul S. M., and Cordell B. (2001) Conversion of brain apolipoprotein E to an insoluble form in a mouse model of Alzheimer disease. Neuroreport 12, 1265–1270.

    Article  PubMed  CAS  Google Scholar 

  • Nakai M., Kawamata T., Taniguchi T., Maeda K., and Tanaka C. (1996) Expression of apolipoprotein E mRNA in rat microglia. Neurosci. Lett. 211, 41–44.

    Article  Google Scholar 

  • Namba Y., Tomonaga M., Kawasaki H., Otomo E., and Ikeda K. (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541, 163–166.

    Article  PubMed  CAS  Google Scholar 

  • Naslund J., Thyberg J., Tjernberg L. O., Wernstedt C., Karlstrom A. R., Bogdanovic N., et al. (1995a) Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer’s disease brain. Neuron 15, 219–228.

    Article  PubMed  CAS  Google Scholar 

  • Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W., and Pitas R. E. (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264, 850–852.

    Article  PubMed  CAS  Google Scholar 

  • Nathan B. P., Chang K. C., Bellosta S., Brisch E., Ge N., Mahley R. W., and Pitas R. E. (1995) The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270, 19,791–19,799.

    Article  CAS  Google Scholar 

  • Nieto-Sampedro M. and Mora F. (1994) Active microglia, sick astroglia and Alzheimer type dementias. Neuroreport 5, 375–380.

    Article  PubMed  CAS  Google Scholar 

  • Nixon R. A. (2000) A “protease activation cascade” in the pathogenesis of Alzheimer’s disease. Ann. NY Acad. Sci. 924, 117–131.

    Article  PubMed  CAS  Google Scholar 

  • Ohkubo N., Mitsuda N., Tamatani M., Yamaguchi A., Lee Y. D., Ogihara T., et al. (2000) Apolipoprotein E4 stimulates CREB’s transcriptional activity through the ERK pathway. J. Biol. Chem. 20, 20.

    Google Scholar 

  • Paka L., Goldberg I. J., Obunike J. C., Choi S. Y., Saxena U., Goldberg I. D., and Pillarisetti S. (1999) Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth? J. Biol. Chem. 274, 36,403–36,408.

    CAS  Google Scholar 

  • Pedersen W. A., Chan S. L., and Mattson M. P. (2000) A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 74, 1426–1433.

    Article  PubMed  CAS  Google Scholar 

  • Pillot T., Goethals M., Najib J., Labeur C., Lins L., Chambaz J., et al. (1999) Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer’s disease. J. Neurochem. 72, 230–237.

    Article  PubMed  CAS  Google Scholar 

  • Poirier J. (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci. 17, 525–530.

    Article  PubMed  CAS  Google Scholar 

  • Ramassamy C., Averill D., Beffert U., Theroux L., Lussier-Cacan S., Cohn J. S., et al. (2000) Oxidative insults are associated with apolipoprotein E genotype in Alzheimer’s disease brain. Neurobiol. Dis. 7, 23–37.

    Article  PubMed  CAS  Google Scholar 

  • Rebeck G. W., Kindy M., and LaDu M. J. (2002) Apolipoprotein E and Alzheimer’s disease: The protective effects of ApoE2 and E3. J. Alzheimer’s Dis. 4, 145–154.

    CAS  Google Scholar 

  • Rebeck G. W., Reiter J. S., Strickland D. K., and Hyman B. T. (1993) Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11, 575–580.

    Article  PubMed  CAS  Google Scholar 

  • Schellenberg G. D. (1995) Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc. Natl. Acad. Sci. U.S.A. 92, 8552–8559.

    Article  PubMed  CAS  Google Scholar 

  • Stannard A. K., Riddell D. R., Sacre S. M., Tagalakis A. D., Langer C., von Eckardstein A., et al. (2001) Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J. Biol. Chem. 276, 46,011–46,016.

    Article  CAS  Google Scholar 

  • Strittmatter W. J., Saunders A. M., Schmechel D., Pericak V. M., Enghild J., Salvesen G. S., and Roses A. D. (1993a) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977–1981.

    Article  PubMed  CAS  Google Scholar 

  • Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong J. M., Salvesen G. S., Pericak-Vance M., et al. (1993b) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098–8102.

    Article  PubMed  CAS  Google Scholar 

  • Strittmatter W. J., Saunders A. M., Goedert M., Weisgraber K. H., Dong L. M., Jakes R., et al. (1994a) Isoform-specific interactions of apolipoprotein E with micro-tubule-associated protein tau: implications for Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 11183–11186.

    Article  PubMed  CAS  Google Scholar 

  • Strittmatter W. J., Weisgraber K. H., Goedert M., Saunders A. M., Huang D., Corder E. H., et al. (1994b) Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp. Neurol. 125, 163–171 (Discussion, 172–174).

    Article  PubMed  CAS  Google Scholar 

  • Tesseur I., Van Dorpe J., Bruynseels K., Bronfman F., Sciot R., Van Lommel A., and Van Leuven F. (2000a) Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am. J. Pathol. 157, 1495–1510.

    PubMed  CAS  Google Scholar 

  • Tesseur I., Van Dorpe J., Spittaels K., Van den Haute C., Moechars D., and Van Leuven F. (2000b) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am. J. Pathol. 156, 951–964.

    PubMed  CAS  Google Scholar 

  • Teter B., Raber J., Nathan B., and Crutcher K. A. (2002) The presence of apoE4, not the absence of apoE3, contributes to AD pathology. J. Alzheimer’s Dis. 4, 155–163.

    CAS  Google Scholar 

  • Teter B., Xu P. T., Gilbert J. R., Roses A. D., Galasko D., and Cole G. M. (1999) Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. J. Neurochem. 73, 2613–2616.

    Article  PubMed  CAS  Google Scholar 

  • Tolar M., Keller J. N., Chan S., Mattson M. P., Marques M. A., and Crutcher K. A. (1999) Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J. Neurosci. 19, 7100–7110.

    PubMed  CAS  Google Scholar 

  • Tolar M., Marques M. A., Harmony J. A., and Crutcher K. A. (1997) Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J. Neurosci. 17, 5678–5686.

    PubMed  CAS  Google Scholar 

  • Uchihara T., Duyckaerts C., He Y., Kobayashi K., Seilhean D., Amouyel P., and Hauw J. J. (1995) ApoE immunoreactivity and microglial cells in Alzheimer’s disease brain. Neurosci. Lett. 195, 5–8.

    Article  PubMed  CAS  Google Scholar 

  • Veinbergs I., Everson A., Sagara Y., and Masliah E. (2002) Neurotoxic effects of apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. J. Neurosci. Res. 67, 379–387.

    Article  PubMed  CAS  Google Scholar 

  • Vogel T., Guo N. H., Guy R., Drezlich N., Krutzsch H. C., Blake D. A., et al. (1994) Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J. Cell. Biochem. 54, 299–308.

    Article  PubMed  CAS  Google Scholar 

  • Weisgraber K. H. (1994) Apolipoprotein E: structure-function relationships. Adv. Protein. Chem. 45, 249–302.

    Article  PubMed  CAS  Google Scholar 

  • Wetterau J. R., Aggerbeck L. P., Rall S. C., and Weisgraber K. H. (1988) Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem. 263, 6240–6248.

    PubMed  CAS  Google Scholar 

  • Whitson J. S., Mims M. P., Strittmatter W. J., Yamaki T., Morrisett J. D., and Appel S. H. (1994) Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E. Biochem. Biophys. Res. Commun. 199, 163–170.

    Article  PubMed  CAS  Google Scholar 

  • Wisniewski H. M. and Wegiel J. (1994) The role of microglia in amyloid fibril formation. Neuropathol. Appl. Neurobiol. 20, 192–194.

    PubMed  CAS  Google Scholar 

  • Wisniewski T., Golabek A., Matsubara E., Ghiso J., and Frangione B. (1993) Apolipoprotein E: binding to soluble Alzheimer’s beta-amyloid. Biochem. Biophys. Res. Commun. 192, 359–365.

    Article  PubMed  CAS  Google Scholar 

  • Wisniewski T., Lalowski M., Golabek A., Vogel T., and Frangione B. (1995) Is Alzheimer’s disease an apolipoprotein E amyloidosis? Lancet 345, 956–958.

    Article  PubMed  CAS  Google Scholar 

  • Xu Q., Li Y., Cyras C., Sanan D. A., and Cordell B. (2000) Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. J. Biol. Chem. 275, 31,770–31,777.

    CAS  Google Scholar 

  • Ye S. Q., Olson L. M., Reardon C. A., and Getz G. S. (1992) Human plasma lipoproteins regulate apolipoprotein E secretion from a post-Golgi compartment. J. Biol. Chem. 267, 21,961–21,966.

    CAS  Google Scholar 

  • Ye S. Q., Reardon C. A., and Getz G. S. (1993) Inhibition of apolipoprotein E degradation in a post-Golgi compartment by a cysteine protease inhibitor. J. Biol. Chem. 268, 8497–8502.

    PubMed  CAS  Google Scholar 

  • Zeleny M., Swertfeger D. K., Weisgraber K. H., and Hui D. Y. (2002) Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation. Biochemistry 41, 11820–11823.

    Article  PubMed  CAS  Google Scholar 

  • Zhang D., McQuade J.-A., Shockley K. P., Marques M. A., and Crutcher K. A. (2001) Proteolysis of apolipoprotein E and Alzheimer’s disease pathology. Alzheimer’s Rep. 4, 67–79.

    Google Scholar 

  • Zhu B., Kuhel D. G., Witte D. P., and Hui D. Y. (2000) Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice. Am. J. Pathol. 157, 1839–1848.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ApoLogic, Inc., Highland Avenue, Suite 3235, 45219-2333, Cincinnati, OH

    Marcos A. Marques & Keith A. Crutcher

  2. Department of Neurosurgery, University of Cincinnati, 45237-0515, Cincinnati, OH

    Keith A. Crutcher

Authors
  1. Marcos A. Marques
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith A. Crutcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith A. Crutcher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marques, M.A., Crutcher, K.A. Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer’s disease. J Mol Neurosci 20, 327–337 (2003). https://doi.org/10.1385/JMN:20:3:327

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/JMN:20:3:327

Index Entries

Search

Navigation